Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharmaceutical company focused on advanced therapies for the sports medicine and severe burn care markets. Its news flow centers on financial performance, adoption of its cell therapy and biologic products, and progress in clinical and manufacturing initiatives.
Investors following VCEL news can expect regular quarterly earnings releases detailing total revenue, product-level revenue for MACI and Burn Care (Epicel and NexoBrid), gross margin, net income or loss, adjusted EBITDA and operating cash flow. Vericel frequently provides financial guidance ranges for full-year revenue, MACI growth, gross margin and adjusted EBITDA margin, and may update these expectations as the year progresses.
Company updates also highlight operational metrics such as record MACI revenue, numbers of MACI implants and biopsies, growth in trained MACI Arthro surgeons, Epicel and NexoBrid biopsy and hospital order trends, and expansion of the MACI sales force. These disclosures offer insight into market penetration and utilization of Vericel’s therapies in orthopedic and burn care settings.
Vericel news items often include information on clinical and regulatory milestones, such as FDA IND clearance for the Phase 3 MACI Ankle clinical study and the initiation of the MACI Ankle MASCOT clinical trial. The company also announces participation in major investor and healthcare conferences, including events hosted by J.P. Morgan, Stephens, Wells Fargo and Truist Securities, where management discusses business performance and strategy.
This VCEL news page aggregates these press releases and related announcements so readers can review historical and recent developments around Vericel’s financial results, product adoption, clinical programs and corporate presentations in one place.
Vericel Corporation (NASDAQ:VCEL) appointed Jonathan Siegal as Principal Accounting Officer, effective February 16, 2022. Siegal, previously Vice President and Corporate Controller, joined Vericel in September 2021 and brings over 20 years of accounting experience across multiple industries. He held various leadership roles, including Global Controller for Lantheus Medical Imaging. CFO Joe Mara commended Siegal's extensive background in strengthening Vericel's finance team, reflecting the company’s commitment to enhancing its financial leadership.
Vericel Corporation (NASDAQ:VCEL) reported a 26% revenue growth in 2021, achieving total net revenue of $156.2 million. For Q4 2021, net revenue was $47.6 million, a 5% increase year-over-year. While MACI revenue reached $111.6 million and Epicel revenue hit $41.5 million, the company reported a net loss of $7.5 million for the year. Looking ahead, Vericel anticipates 2022 revenues between $178 million and $189 million with a gross margin of approximately 70%. A conference call is scheduled for today at 8:30 AM ET.
Vericel Corporation (NASDAQ:VCEL) announced a conference call on February 24, 2022 at 8:30 AM EST to discuss its fourth-quarter 2021 financial results and business highlights. The call will be accessible via the Investor Relations section of their website. Vericel specializes in advanced therapies in sports medicine and severe burn care, offering products like MACI® and Epicel®. A replay of the call will be available until February 28, 2022.
Vericel Corporation (NASDAQ:VCEL) has announced a long-term lease for a new 125,000 square foot facility in Burlington, Massachusetts, which will serve as its advanced cell therapy manufacturing and corporate headquarters. This state-of-the-art facility will enhance the company’s manufacturing capacity for its products MACI® and Epicel®, supporting long-term revenue growth. Expected completion is in 2024, with production starting in 2025. The facility aims to meet LEED Gold and Fitwel Level 2 certifications, reinforcing the company’s commitment to environmentally responsible operations.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. Eastern Time. This esteemed conference is a significant platform for healthcare companies to share insights and updates.
A webcast of the presentation will be accessible on the Investor Relations section of Vericel's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18 at 10:00 AM ET. This event aims to showcase advancements in medical technology and health services.
A webcast of the presentation will be accessible on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ: VCEL) reported third quarter 2021 net revenue of $34.5 million, a 7% increase from $32.3 million in Q3 2020. Year-to-date revenue rose 38% to $108.6 million. Notably, MACI revenue was $23.9 million, and Epicel revenue was $9.8 million. The company faced a net loss of $4.9 million or $0.11 per share, contrasting with net income of $3.6 million in Q3 2020. Gross margin decreased to 64%, down from 70% the previous year. The company adjusted its full-year revenue guidance to reflect a projected increase of 27%-30%.
Vericel Corporation (NASDAQ:VCEL) has announced a webcast and conference call to discuss its third-quarter 2021 financial results and business highlights. The call is scheduled for November 9, 2021, at 8:30 AM EDT. Investors can access the call live via the company's Investor Relations website. Vericel operates in advanced therapies for sports medicine and severe burn care, marketing two cell therapy products: MACI® and Epicel®. The company also holds the exclusive North American commercial rights for NexoBrid®, aimed at severe burn treatment.
Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference. The event is scheduled for Monday, September 13, 2021, at 4:15 p.m. Eastern Time. Investors can access the webcast through the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®. For further details, visit www.vcel.com.
Vericel Corporation (NASDAQ:VCEL) has appointed Patrick J. Fowler as Senior Vice President of Corporate Development and Strategy, effective immediately. With over 15 years of experience in business development within the biotech sector, Fowler previously led strategy and operations at Sanofi, enhancing corporate growth and development strategies. The company anticipates Fowler's expertise will drive growth and enhance its innovative product portfolio, which includes MACI® and Epicel® for sports medicine and burn care.